TP53 (Ab-46) Antibody

What is the TP53 (Ab-46) antibody and what epitope does it target?

The TP53 (Ab-46) antibody is a phospho-specific antibody that recognizes p53 protein phosphorylated at serine 46 (pSer46). This antibody is typically produced in rabbit as an affinity isolated antibody and targets the specific phosphorylation site that plays a crucial role in p53-mediated apoptotic responses. The antibody specifically recognizes the phosphorylated form of p53 and can be used to distinguish between phosphorylated and non-phosphorylated states of the protein .

What is the functional significance of p53 phosphorylation at serine 46?

Phosphorylation of p53 at serine 46 is specifically associated with the regulation of p53's ability to induce apoptosis rather than cell cycle arrest. This phosphorylation event occurs in response to severe DNA damage and reinforces p53's pro-apoptotic functions. The Ser46 phosphorylation is considered a critical modification that helps determine cellular fate between repair and survival versus programmed cell death, making it an important target for cancer research . This post-translational modification represents one of the regulatory mechanisms that fine-tune p53 function in response to cellular stress.

How does TP53 (Ab-46) antibody differ from other p53 antibodies?

TP53 (Ab-46) antibody specifically recognizes the phosphorylated serine 46 residue of p53, distinguishing it from antibodies targeting total p53 or other phosphorylation sites. While general p53 antibodies (like DO-1, DO-7, or PAb1801) recognize unmodified epitopes regardless of phosphorylation status, phospho-specific antibodies like TP53 (Ab-46) provide information about specific activation states of p53 . Other common phospho-specific p53 antibodies include those targeting pSer15, pSer20, and pSer392, each correlating with different aspects of p53 activity and regulation after cellular stress .

What are the optimal conditions for using TP53 (Ab-46) antibody in Western blot applications?

For Western blotting applications, the recommended dilution of TP53 (Ab-46) antibody is typically 1:500-1:1000 . Optimal results are achieved when:

• Using PVDF membrane rather than nitrocellulose

• Blocking with 5% BSA in TBST rather than milk (which contains phosphatases)

• Including phosphatase inhibitors in sample preparation buffers

• Using positive controls such as extracts from MCF-7 cells treated with camptothecin (1 μM for 5 hours), which induces Ser46 phosphorylation

The expected molecular weight for detection is approximately 53 kDa. To verify signal specificity, lambda phosphatase treatment can be used as a negative control, as this will abolish the phospho-specific signal while total p53 remains detectable .

How can I optimize TP53 (Ab-46) antibody for immunohistochemistry applications?

For immunohistochemistry applications using the TP53 (Ab-46) antibody:

• Use formalin-fixed paraffin-embedded (FFPE) sections with optimal fixation time (12-24 hours in 10% neutral buffered formalin)

• Perform appropriate antigen retrieval (heat-induced epitope retrieval at pH 9.0)

• Apply the antibody at a concentration of approximately 1.7-15 μg/mL

• Incubate overnight at 4°C for optimal signal-to-noise ratio

• Use HRP-DAB detection systems with appropriate counterstains

Studies have shown that pre-analytic variables like fixation time and cold ischemia can affect phospho-epitope preservation. Xenograft experiments have demonstrated that phospho-p53 epitopes are particularly sensitive to delayed fixation beyond 4 hours of cold ischemia . This highlights the importance of proper tissue handling for phospho-epitope detection.

What controls should be included when using TP53 (Ab-46) antibody in research applications?

For rigorous experimental design with TP53 (Ab-46) antibody, include these controls:

This comprehensive control scheme helps ensure reliable and interpretable results when working with phospho-specific antibodies.

How can TP53 (Ab-46) antibody be used to distinguish between wild-type and mutant p53 functions?

The TP53 (Ab-46) antibody can be valuable for distinguishing functional aspects of wild-type versus mutant p53:

• Wild-type p53 shows inducible Ser46 phosphorylation following DNA damage, whereas many mutant p53 proteins show altered phosphorylation patterns

• By combining TP53 (Ab-46) antibody with total p53 antibodies, researchers can calculate the ratio of phosphorylated to total p53, which is often dysregulated in cancer cells

• In cells harboring missense TP53 mutations, the mutant protein may show aberrant phosphorylation at Ser46, either constitutively or in response to stress

Research has shown that many p53 missense mutations (particularly "contact mutations" like R248W and R273H) retain the ability to be phosphorylated but show altered downstream responses, while structural/conformational mutations (like R175H) may show different phosphorylation patterns altogether . This can be leveraged to study gain-of-function properties of mutant p53.

What is the relationship between p53 Ser46 phosphorylation and cellular outcomes in different cancer types?

The relationship between p53 Ser46 phosphorylation and cellular outcomes varies by cancer type:

• In breast cancer, p53 Ser46 phosphorylation correlates with apoptotic response to DNA-damaging therapies, and detection of phospho-Ser46 in tissue samples can have prognostic value .

• In colorectal cancer cell lines with wild-type TP53, irradiation induces Ser46 phosphorylation followed by p21 induction, though the increase in total p53 levels varies between cell lines . This suggests that phosphorylation can occur without massive protein stabilization.

• In thyroid cancers, particularly anaplastic thyroid carcinoma (ATC), TP53 mutations are common (significantly higher than control groups, OR 8.95; 95% CI 1.36–58.70), potentially affecting phosphorylation-dependent functions .

• In prostate cancer, phospho-specific antibodies including those targeting Ser46 can help identify subclonal TP53 missense mutations that may have prognostic significance .

The cellular outcome (apoptosis vs. cell cycle arrest) appears to be influenced by the extent and duration of Ser46 phosphorylation, as well as the broader phosphorylation pattern across multiple sites.

How can proximity ligation assay (PLA) using TP53 (Ab-46) antibody enhance detection of p53 phosphorylation events?

Proximity ligation assay (PLA) using TP53 (Ab-46) antibody paired with total p53 antibody offers several advantages:

• Single-molecule resolution: PLA can detect individual phosphorylated p53 molecules, enabling quantification of rare phosphorylation events at the single-cell level

• Improved specificity: By requiring proximity between two epitopes (phospho-Ser46 and another p53 epitope), PLA reduces false positives compared to single-antibody detection methods

• Spatial information: PLA reveals the subcellular localization of phosphorylated p53, which can differ between normal activation and pathological states

• Higher sensitivity: Typical PLA protocols can detect lower levels of phosphorylated proteins than conventional immunofluorescence

Companies like Abnova offer phosphorylation antibody pair sets specifically designed for PLA, containing rabbit polyclonal antibodies against phospho-TP53 Ser46 and mouse monoclonal antibodies against total TP53 . This approach has been successfully used to visualize p53 phosphorylation events in HeLa cells, where each red dot in the assay represents a single phosphorylated protein molecule.

How can I address non-specific binding when using TP53 (Ab-46) antibody?

Non-specific binding with TP53 (Ab-46) antibody can be addressed through these methodological approaches:

• Optimize antibody concentration: Titrate the antibody (starting from 1:1000 dilution for Western blot) to identify the minimal concentration that yields specific signal

• Improve blocking: Use 5% BSA rather than milk for phospho-epitopes, and consider extended blocking times (2+ hours at room temperature)

• Increase washing stringency: Add 0.1% SDS or increase Tween-20 concentration to 0.2% in wash buffers for Western blots

• Pre-adsorb the antibody: Incubate with extracts from p53-null cells to remove antibodies that might cross-react with other proteins

• Verify specificity with phosphatase treatment: Treat one sample with lambda phosphatase to confirm the signal is phosphorylation-dependent

• Include peptide competition: Use a phosphorylated Ser46 peptide to confirm epitope specificity

Remember that some phospho-specific antibodies may cross-react with similar phosphorylated motifs in other proteins, so multiple validation approaches are recommended.

What factors can lead to false negative results when using TP53 (Ab-46) antibody in tissue samples?

False negative results with TP53 (Ab-46) antibody in tissue samples can arise from:

• Pre-analytical variables: Studies show that phospho-epitopes, including p53 Ser46, are highly sensitive to:

  • Prolonged cold ischemia (>4 hours) before fixation

  • Inadequate fixation time (<12 hours in 10% NBF)

  • Overfixation (>48 hours) leading to excessive crosslinking

• Processing issues:

  • Improper antigen retrieval (pH-dependent epitope masking)

  • Suboptimal deparaffinization

  • Endogenous phosphatase activity during processing

• Biological factors:

  • Low basal phosphorylation levels without appropriate cellular stress

  • Mutation-specific effects (certain mutations may alter antibody recognition sites)

  • Cell type-specific phosphorylation patterns

A study examining pre-analytic variables using VCaP and Du145 xenografts demonstrated that phospho-epitopes show significant degradation after delayed fixation, highlighting the critical importance of rapid tissue preservation for phospho-specific detection .

How should I interpret discordant results between TP53 (Ab-46) antibody and other p53 detection methods?

When facing discordant results between TP53 (Ab-46) antibody and other p53 detection methods:

• Recognize method-specific limitations:

  • IHC with TP53 (Ab-46) detects only the phosphorylated form, which may be transient

  • Total p53 IHC patterns (overexpression, complete absence, or wild-type staining) correlate with specific mutation types but don't indicate phosphorylation status

  • Genetic sequencing identifies TP53 mutations but cannot determine protein phosphorylation states

• Consider biological explanations:

  • Wild-type p53 may show inducible Ser46 phosphorylation under stress conditions

  • Certain TP53 mutations may retain phosphorylation capabilities while losing transcriptional activity

  • Post-translational modifications can occur independently of protein accumulation

• Implement integrated analysis:

  • Correlate phospho-Ser46 signal with total p53 levels

  • Compare with other phosphorylation sites (Ser15, Ser20) that may show different patterns

  • Evaluate downstream targets (p21, BAX, PUMA) to assess functional outcomes

How does the detection of phospho-Ser46 p53 correlate with clinical outcomes in cancer patients?

The correlation between phospho-Ser46 p53 detection and clinical outcomes reveals significant prognostic value:

• In breast cancer, phospho-Ser46 detection in tumor samples correlates with:

  • Response to DNA-damaging chemotherapeutics

  • Increased apoptotic index

  • Patient survival outcomes when combined with other p53 status markers

• In prostate cancer:

  • p53 IHC (including phospho-specific detection) can identify tumors with high risk of metastasis

  • In a cohort study of men with biochemical recurrence after radical prostatectomy, the multivariable hazard ratio for metastasis among cases with p53 accumulation was 2.55 (95% CI: 1.1–5.91)

• In colorectal cancer:

  • Wild-type TP53 tumors typically show inducible Ser46 phosphorylation after radiation

  • Altered phosphorylation patterns may indicate functional p53 pathway disruption even in the absence of mutations

While most clinical studies have focused on total p53 accumulation rather than specific phosphorylation sites, emerging research suggests that phospho-specific detection provides additional stratification potential for treatment selection and prognosis prediction.

How can TP53 (Ab-46) antibody be used in conjunction with other biomarkers for improved cancer diagnosis?

TP53 (Ab-46) antibody can enhance cancer diagnosis when used in multiparameter panels:

• Integrated diagnostic panels:

  • Combine phospho-Ser46 detection with total p53 IHC pattern (overexpression, complete absence, or wild-type)

  • Include MDM2 detection (p53 regulator) to assess pathway integrity

  • Add p21 staining to evaluate downstream transcriptional activity

• Multi-level molecular profiling:

  • Combine with TP53 sequencing data to correlate mutation type with phosphorylation status

  • Integrate with other genomic biomarkers (e.g., BRCA1/2 in ovarian cancer)

  • Correlate with serum p53 antibodies, which are associated with TP53 missense mutations and may serve as early detection biomarkers

• Cancer-specific applications:

  • In ovarian cancer, optimized p53 IHC approaches 100% specificity for TP53 mutation with high negative predictive value (97%), helping distinguish high-grade from low-grade serous carcinomas

  • In thyroid cancer, p53 overexpression is significantly more frequent in anaplastic thyroid carcinoma compared to controls (OR 64.37; 95% CI 27.28–151.89), making it valuable for distinguishing aggressive subtypes

The combination of phospho-specific antibodies with other biomarkers provides a more comprehensive assessment of p53 pathway functionality than any single marker alone.

What are the methodological considerations for using TP53 (Ab-46) antibody in translational research studies?

For translational research involving TP53 (Ab-46) antibody, several methodological considerations are critical:

• Tissue collection protocols:

  • Implement rapid fixation (<2 hours cold ischemia) to preserve phospho-epitopes

  • Standardize fixation times (12-24 hours in 10% NBF)

  • Consider alternative preservation methods like PAXgene fixation for phosphoprotein studies

• Assay validation requirements:

  • Perform analytic validation using cell lines with known TP53 status (like the NCI-60 panel)

  • Include pre-analytical validation with controlled ischemia and fixation conditions

  • Conduct clinical validation against gold-standard methods

• Standardized scoring systems:

  • Define clear positivity thresholds (e.g., >10% nuclear labeling for p53)

  • Implement digital image analysis for quantitative assessment

  • Use H-score or allred scoring systems to account for both intensity and percentage of positive cells

• Quality control measures:

  • Include on-slide positive and negative controls

  • Participate in external quality assessment programs

  • Perform regular inter-observer concordance testing

A comprehensive validation study of p53 IHC in prostate cancer demonstrated that careful attention to these methodological details resulted in 100% sensitivity for detection of TP53 missense mutations in the NCI-60 panel and 84% positive predictive value in FFPE prostate tumors .